Cargando…

Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study

BACKGROUND: Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines display of real time adherence data and behaviour change techniques. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hind, Daniel, Drabble, Sarah J., Arden, Madelynne A., Mandefield, Laura, Waterhouse, Simon, Maguire, Chin, Cantrill, Hannah, Robinson, Louisa, Beever, Daniel, Scott, Alexander J., Keating, Sam, Hutchings, Marlene, Bradley, Judy, Nightingale, Julia, Allenby, Mark I., Dewar, Jane, Whelan, Pauline, Ainsworth, John, Walters, Stephen J., O’Cathain, Alicia, Wildman, Martin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458785/
https://www.ncbi.nlm.nih.gov/pubmed/30975206
http://dx.doi.org/10.1186/s12890-019-0834-6
_version_ 1783410082566897664
author Hind, Daniel
Drabble, Sarah J.
Arden, Madelynne A.
Mandefield, Laura
Waterhouse, Simon
Maguire, Chin
Cantrill, Hannah
Robinson, Louisa
Beever, Daniel
Scott, Alexander J.
Keating, Sam
Hutchings, Marlene
Bradley, Judy
Nightingale, Julia
Allenby, Mark I.
Dewar, Jane
Whelan, Pauline
Ainsworth, John
Walters, Stephen J.
O’Cathain, Alicia
Wildman, Martin J.
author_facet Hind, Daniel
Drabble, Sarah J.
Arden, Madelynne A.
Mandefield, Laura
Waterhouse, Simon
Maguire, Chin
Cantrill, Hannah
Robinson, Louisa
Beever, Daniel
Scott, Alexander J.
Keating, Sam
Hutchings, Marlene
Bradley, Judy
Nightingale, Julia
Allenby, Mark I.
Dewar, Jane
Whelan, Pauline
Ainsworth, John
Walters, Stephen J.
O’Cathain, Alicia
Wildman, Martin J.
author_sort Hind, Daniel
collection PubMed
description BACKGROUND: Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines display of real time adherence data and behaviour change techniques. METHODS: Design: Pilot, open-label, parallel-group RCT with concurrent semi-structured interviews. Participants: PWCF at two Cystic Fibrosis (CF) units. Eligible: aged 16 or older; on the CF registry. Ineligible: post-lung transplant or on the active list; unable to consent; using dry powder inhalers. Interventions: Central randomisation on a 1:1 allocation to: (1) intervention, linking nebuliser use with data recording and transfer capability to a software platform, and behavioural strategies to support self-management delivered by trained interventionists (n = 32); or, (2) control, typically face-to-face meetings every 3 months with CF team (n = 32). Outcomes: RCT feasibility defined as: recruitment of ≥ 48 participants (75% of target) in four months (pilot primary outcome); valid exacerbation data available for ≥ 85% of those randomised (future RCT primary outcome); change in % medication adherence; FEV(1) percent predicted (key secondaries in future RCT); and perceptions of trial procedures, in semi-structured interviews with intervention (n = 14) and control (n = 5) participants, interventionists (n = 3) and CF team members (n = 5). RESULTS: The pilot trial recruited to target, randomising 33 to intervention and 31 to control in the four-month period, June–September 2016. At study completion (30th April 2017), 60 (94%; Intervention = 32, Control =28) participants contributed good quality exacerbation data (intervention: 35 exacerbations; control: 25 exacerbation). The mean change in adherence and baseline-adjusted FEV(1) percent predicted were higher in the intervention arm by 10% (95% CI: -5.2 to 25.2) and 5% (95% CI -2 to 12%) respectively. Five serious adverse events occurred, none related to the intervention. The mean change in adherence was 10% (95% CI: -5.2 to 25.2), greater in the intervention arm. Interventionists delivered insufficient numbers of review sessions due to concentration on participant recruitment. This left interventionists insufficient time for key intervention procedures. A total of 10 key changes that were made to RCT procedures are summarised. CONCLUSIONS: With improved research processes and lower monthly participant recruitment targets, a full-scale trial is feasible. TRIAL REGISTRATION: ISRCTN13076797. Prospectively registered on 07/06/2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-019-0834-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6458785
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64587852019-04-22 Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study Hind, Daniel Drabble, Sarah J. Arden, Madelynne A. Mandefield, Laura Waterhouse, Simon Maguire, Chin Cantrill, Hannah Robinson, Louisa Beever, Daniel Scott, Alexander J. Keating, Sam Hutchings, Marlene Bradley, Judy Nightingale, Julia Allenby, Mark I. Dewar, Jane Whelan, Pauline Ainsworth, John Walters, Stephen J. O’Cathain, Alicia Wildman, Martin J. BMC Pulm Med Research Article BACKGROUND: Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines display of real time adherence data and behaviour change techniques. METHODS: Design: Pilot, open-label, parallel-group RCT with concurrent semi-structured interviews. Participants: PWCF at two Cystic Fibrosis (CF) units. Eligible: aged 16 or older; on the CF registry. Ineligible: post-lung transplant or on the active list; unable to consent; using dry powder inhalers. Interventions: Central randomisation on a 1:1 allocation to: (1) intervention, linking nebuliser use with data recording and transfer capability to a software platform, and behavioural strategies to support self-management delivered by trained interventionists (n = 32); or, (2) control, typically face-to-face meetings every 3 months with CF team (n = 32). Outcomes: RCT feasibility defined as: recruitment of ≥ 48 participants (75% of target) in four months (pilot primary outcome); valid exacerbation data available for ≥ 85% of those randomised (future RCT primary outcome); change in % medication adherence; FEV(1) percent predicted (key secondaries in future RCT); and perceptions of trial procedures, in semi-structured interviews with intervention (n = 14) and control (n = 5) participants, interventionists (n = 3) and CF team members (n = 5). RESULTS: The pilot trial recruited to target, randomising 33 to intervention and 31 to control in the four-month period, June–September 2016. At study completion (30th April 2017), 60 (94%; Intervention = 32, Control =28) participants contributed good quality exacerbation data (intervention: 35 exacerbations; control: 25 exacerbation). The mean change in adherence and baseline-adjusted FEV(1) percent predicted were higher in the intervention arm by 10% (95% CI: -5.2 to 25.2) and 5% (95% CI -2 to 12%) respectively. Five serious adverse events occurred, none related to the intervention. The mean change in adherence was 10% (95% CI: -5.2 to 25.2), greater in the intervention arm. Interventionists delivered insufficient numbers of review sessions due to concentration on participant recruitment. This left interventionists insufficient time for key intervention procedures. A total of 10 key changes that were made to RCT procedures are summarised. CONCLUSIONS: With improved research processes and lower monthly participant recruitment targets, a full-scale trial is feasible. TRIAL REGISTRATION: ISRCTN13076797. Prospectively registered on 07/06/2016. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-019-0834-6) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-11 /pmc/articles/PMC6458785/ /pubmed/30975206 http://dx.doi.org/10.1186/s12890-019-0834-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hind, Daniel
Drabble, Sarah J.
Arden, Madelynne A.
Mandefield, Laura
Waterhouse, Simon
Maguire, Chin
Cantrill, Hannah
Robinson, Louisa
Beever, Daniel
Scott, Alexander J.
Keating, Sam
Hutchings, Marlene
Bradley, Judy
Nightingale, Julia
Allenby, Mark I.
Dewar, Jane
Whelan, Pauline
Ainsworth, John
Walters, Stephen J.
O’Cathain, Alicia
Wildman, Martin J.
Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
title Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
title_full Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
title_fullStr Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
title_full_unstemmed Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
title_short Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
title_sort supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458785/
https://www.ncbi.nlm.nih.gov/pubmed/30975206
http://dx.doi.org/10.1186/s12890-019-0834-6
work_keys_str_mv AT hinddaniel supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT drabblesarahj supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT ardenmadelynnea supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT mandefieldlaura supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT waterhousesimon supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT maguirechin supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT cantrillhannah supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT robinsonlouisa supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT beeverdaniel supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT scottalexanderj supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT keatingsam supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT hutchingsmarlene supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT bradleyjudy supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT nightingalejulia supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT allenbymarki supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT dewarjane supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT whelanpauline supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT ainsworthjohn supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT waltersstephenj supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT ocathainalicia supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy
AT wildmanmartinj supportingmedicationadherenceforadultswithcysticfibrosisarandomisedfeasibilitystudy